EXHIBIT 99.1
Proteon Therapeutics Announces Third Quarter 2016 Financial Results
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2016, and recent business highlights.
“We are making strong progress in our Phase 3 program for investigational vonapanitase,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “PATENCY-1 top-line results are expected in December, and our second Phase 3 trial, PATENCY-2, is on track to complete patient enrollment in the first quarter of 2017.”
Recent Highlights for 2016
Overview of Phase 1 clinical program of vonapanitase in peripheral artery disease (PAD) presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference. Dr. Ehrin J. Armstrong, Associate Professor, Medicine-Cardiology at University of Colorado School of Medicine and Director, Interventional Cardiology VA Eastern Colorado Healthcare System, discussed Proteon’s two additional Phase 1 clinical studies evaluating vonapanitase in patients with PAD. These multicenter, dose-escalation studies will evaluate the safety and technical feasibility of a single administration of vonapanitase as a monotherapy and as an adjunct to angioplasty for patients with PAD.
Board of Directors strengthened with additional operating and leadership expertise. Proteon strengthened its Board of Directors with the appointment of Paul J. Hastings as Chairman. Paul brings substantial experience in the board room having been a lead director and/or chairman at multiple biotechnology companies. He also brings significant operational and commercial experience, having successfully led several biotechnology companies as their chief executive officer.
Key Milestones for 2016 and Early 2017
- Report top-line data in December 2016 for PATENCY-1, the first Phase 3 clinical study of investigational vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (AVF) for hemodialysis.
- Complete enrollment in the first quarter of 2017 for PATENCY-2, the second Phase 3 clinical study of investigational vonapanitase.
Upcoming Events
- Presentation at the Stifel 2016 Healthcare Conference on November 16th at 8:00 a.m. in New York City.
- Participation in the Oppenheimer Life Sciences Summit on November 29th in New York City.
Third Quarter 2016 Financial Results
Cash position: Cash, cash equivalents and available-for-sale investments totaled $47.0 million as of September 30, 2016, compared to $65.3 million as of December 31, 2015. The decrease was driven by operational costs for the first nine-month period of 2016.
R&D expenses: Research and development expenses for the third quarter of 2016 were $4.8 million as compared to $3.1 million for the third quarter of 2015. The increase in R&D expenses was due primarily to increased expenses for our manufacturing pre-validation and validation efforts; increased external clinical expenses related to our ongoing radiocephalic AVF Phase 3 clinical trials and our PAD Phase 1 clinical trials; and increased personnel costs.
G&A expenses: General and administrative expenses for the third quarter of 2016 were $2.3 million as compared to $2.0 million for the third quarter of 2015. The increase in G&A expenses was due primarily to higher personnel costs in the third quarter of 2016 than in the third quarter of 2015.
Net loss: Net loss for the third quarter of 2016 was $7.1 million as compared to $5.4 million for the third quarter of 2015. Net loss included stock-based compensation expense of $0.7 million for the third quarter of 2016 and $0.6 million for the third quarter of 2015.
Financial guidance: The Company expects that its cash, cash equivalents and available-for-sale investments will be sufficient to fund its operations into the fourth quarter of 2017.
About Vonapanitase
Vonapanitase (formerly PRT-201) is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Vonapanitase is applied in a single administration and is currently being studied in two Phase 3 clinical trials, PATENCY-1 and PATENCY-2, in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (AVF) for hemodialysis, and two Phase 1 clinical trials in patients with peripheral artery disease (PAD). Vonapanitase has received fast track and orphan drug designations from the U.S. Food and Drug Administration (FDA), and orphan medicinal product designation from the European Commission, for hemodialysis vascular access indications.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials, PATENCY-1 and PATENCY-2, in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis, and two Phase 1 clinical trials in patients with peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are, or may be deemed to be, "forward-looking statements." In some cases these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “estimates,” “anticipates,” "expects,” “plans,” "intends,” “may,” or “will,” in each case, their negatives or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements, including when the Company expects to report top-line data from the PATENCY-1 Phase 3 clinical study of vonapanitase, the number of patients to be enrolled in and the timing of completion of enrollment in the PATENCY-2 Phase 3 clinical study of vonapanitase, the potential surgical and endovascular applications for vonapanitase, including peripheral artery disease (PAD), the potential treatment of renal and vascular diseases with vonapanitase, the effect of vonapanitase in patients with CKD, whether vonapanitase improves AVF patency, timing of clinical studies of vonapanitase in patients with PAD, the sufficiency of the Company’s cash, cash-equivalents and available-for-sale investments to fund the Company’s operations into the fourth quarter of 2017, and those relating to future events or our future financial performance or condition, involve substantial known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors, including whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements for the period anticipated; whether data from early nonclinical or clinical studies will be indicative of the data that will be obtained from future clinical trials; whether vonapanitase will advance through the clinical trial process on the anticipated timeline and warrant submission for regulatory approval; whether such a submission would receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies on a timely basis or at all; and whether we can successfully commercialize and market our product candidates, are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (“SEC”) on March 14, 2016, and our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as filed with the SEC, particularly in the sections titled “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations.” In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements contained in this press release represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
| Proteon Therapeutics, Inc. | ||||||||||
| Consolidated Balance Sheet Data | ||||||||||
| (In thousands) | ||||||||||
| September 30, | December 31, | |||||||||
| 2016 | 2015 | |||||||||
| Cash, cash equivalents and available-for-sale investments | $ | 46,974 | $ | 65,263 | ||||||
| Prepaid expenses and other current assets | 1,749 | 1,345 | ||||||||
| Property and equipment, net and other non-current assets | 672 | 930 | ||||||||
| Total assets | $ | 49,395 | $ | 67,538 | ||||||
| Accounts payable and accrued expenses | $ | 4,777 | $ | 3,596 | ||||||
| Other liabilities | 98 | 537 | ||||||||
| Preferred stock, common stock and additional paid-in-capital | 197,327 | 194,667 | ||||||||
| Accumulated deficit and accumulated other comprehensive income | (152,807 | ) | (131,262 | ) | ||||||
| Total liabilities and stockholders’ deficit | $ | 49,395 | $ | 67,538 | ||||||
| Proteon Therapeutics, Inc. | ||||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | $ | 4,842 | $ | 3,078 | $ | 14,432 | $ | 8,801 | ||||||||||
| General and administrative | 2,324 | 2,004 | 7,407 | 5,882 | ||||||||||||||
| Total operating expenses | 7,166 | 5,082 | 21,839 | 14,683 | ||||||||||||||
| Loss from operations | (7,166 | ) | (5,082 | ) | (21,839 | ) | (14,683 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||
| Investment income | 46 | 34 | 155 | 111 | ||||||||||||||
| Other (expense) income, net | 13 | (335 | ) | 120 | (463 | ) | ||||||||||||
| Total other (expense) income | 59 | (301 | ) | 275 | (352 | ) | ||||||||||||
| Net loss | $ | (7,107 | ) | $ | (5,383 | ) | $ | (21,564 | ) | $ | (15,035 | ) | ||||||
| Net loss per share attributable to common stockholders - basic and diluted | $ | (0.43 | ) | $ | (0.33 | ) | $ | (1.30 | ) | $ | (0.92 | ) | ||||||
| Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted | 16,582,276 | 16,466,945 | 16,550,483 | 16,455,257 | ||||||||||||||
| (0.43 | ) | |||||||||||||||||
| Supplemental disclosure of stock-based compensation expense and loss from currency forward contracts: | ||||||||||||||||||
| Included in operating expenses, above, are the following amounts for non-cash stock based compensation expense: | ||||||||||||||||||
| Research and development | $ | 168 | $ | 184 | $ | 797 | $ | 431 | ||||||||||
| General and administrative | 519 | 427 | 1,702 | 1,063 | ||||||||||||||
| Total | $ | 687 | $ | 611 | $ | 2,499 | $ | 1,494 | ||||||||||
| Included in other expense, above, are the following amounts from forward foreign currency contracts: | ||||||||||||||||||
| Realized (losses) gains from forward foreign currency contracts | $ | (4 | ) | $ | - | $ | (8 | ) | $ | (14 | ) | |||||||
| Unrealized (losses) gains from forward foreign currency contracts | 2 | (314 | ) | 127 | (426 | ) | ||||||||||||
| Total | $ | (2 | ) | $ | (314 | ) | $ | 119 | $ | (440 | ) | |||||||
Investor Relations Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
geldridge@proteontherapeutics.com
Media Contact
Cara Mayfield, Ten Bridge Communications
857-242-1872
proteon@tenbridgecommunications.com